I’m not a trader, don’t have or want access to OTC level trading platforms and certainly dont profess to have any insight or knowledge to how or why DECN is trading at these levels.
Now with that, IMO “sustainable” selling price appreciation will only result from going to market and generating increasing sales. Focus and control what you can directly and greatly influence. The company may get some bumps along the way on PD progress, partnership announcements and will hopefully get a much needed lift (and capital infusion) when the lawsuit settles, but those will be short lived if they don’t translate to a sustainable business model. A sustainable business model that can either be grown internally or monetized.
I was thinking Q2 would see the initial thrust in sales growth. That may be a bit premature depending on status of GenSure and GenChoice. Does anyone know where these products stand along with timing?
Here’s hoping we get a crisp and clear business update in the Q2 filing.
Now with that, IMO “sustainable” selling price appreciation will only result from going to market and generating increasing sales. Focus and control what you can directly and greatly influence. The company may get some bumps along the way on PD progress, partnership announcements and will hopefully get a much needed lift (and capital infusion) when the lawsuit settles, but those will be short lived if they don’t translate to a sustainable business model. A sustainable business model that can either be grown internally or monetized.
I was thinking Q2 would see the initial thrust in sales growth. That may be a bit premature depending on status of GenSure and GenChoice. Does anyone know where these products stand along with timing?
Here’s hoping we get a crisp and clear business update in the Q2 filing.
5
